Aug. 14 at 10:35 AM
Citizens reiterated
$IMMX Market Outperform-
$23 and said that it sees 273% pot'l⬆️for its bull case (
$42) and 47% pot'l⬇️for its bear case (
$6).
$PRTA $JNJ - GMAB BMY GILD - ACLX AZN ABBV REGN
Citizens said -- We reiterate our Market Outperform rating and price target of
$23 for Immix Biopharma based on a revenue and earnings multiples analysis.
Recently, Immix reported 2Q26 earnings, and based on our conversation with management, we remain confident in regard to the cadence of value-driving milestones over the next 6-12 months.
With NXC-201 on track to report top-line results in September and file a BLA in 1H27, a potential commercial launch by year-end 2026/early 2027, and a solid cash position of
$232.1MM, we believe Immix shares represent an attractive investment opportunity, with ~47% potential downside (bear case
$6) and ~273% potential upside (bull case
$42).
